AXIM® Biotechnologies Appoints New Chief Executive Officer
08 janv. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the...
New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids
23 oct. 2018 09h10 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products
16 oct. 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
New License Allows Leading Cannabinoid Biopharmaceutical Company to Advance Production of Clinical Trial Products NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM®...
AXIM® Biotechnologies Signs LOI for Distribution of Products Throughout Australia and New Zealand
13 sept. 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that it has signed a...
AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics
27 août 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech or the “Company”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
15 août 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability
07 août 2018 08h55 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced positive results from...
AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
28 juin 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company will be...
New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Extraction and Purification of Delta-9-THC For Use in MedChew RX Clinical Program
19 juin 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States...
AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
15 mai 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has reached a long-term...